Left atrial appendage occlusion (LAAO) added to usual care led to a reduction in ischaemic stroke or non-cerebral systemic embolism following cardiac surgery among patients with atrial fibrillation (AF), according to results of the LAAOS* III trial.
Treatment with the HMG-CoA reductase inhibitor atorvastatin in critically ill patients with COVID-19 did not significantly reduce the primary composite outcome of venous or arterial thrombosis risk, treatment with extracorporeal membrane oxygenation (ECMO), or mortality vs placebo in the INSPIRATION-S study presented at ACC.21.
Among patients with newly diagnosed type 2 diabetes, the risk of developing cardiovascular disease (CVD) is elevated in the presence of symptoms indicative of diabetic polyneuropathy, as shown in a study.
Only a small fraction of patients with stable ischaemic heart disease (SIHD) who undergo percutaneous coronary intervention (PCI) in the US meet the inclusion criteria of the ISCHEMIA* trial, according to results of a study presented at SCAI 2021.
New drug applications approved by US FDA as of 01-15 June 2021 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
In patients with acute coronary syndromes, undergoing a more intensive low-density lipoprotein cholesterol (LDL-C)–lowering therapy during the early disease phase leads to a significant decrease in the risk of long-term major adverse cardiac events (MACEs), according to a study. This benefit is more pronounced for patients with higher baseline and larger reduction in LDL-C levels.
In patients who develop chronic graft-versus-host disease (cGVHD) after haematopoietic cell transplantation (HCT), the risk of thromboembolic events (TEE) seems to be affected by disease severity and donor-recipient ABO blood group, a recent study has found.